Cite

HARVARD Citation

    Maruyama, D. et al. (2022). Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer science. 113 (9), pp. 3267-3270. [Online]. 
  
Back to record